Intravenous Fosfomycin for Systemic Multidrug-Resistant <i<Pseudomonas aeruginosa</i< Infections

Human <i<Pseudomonas</i< infections have high morbidity and mortality rates. <i<Pseudomonas</i< bacteria can cause sepsis or septic shock; they produce biofilm and commonly exhibit a multidrug-resistant phenotype. The choice of antimicrobial therapy in many cases is challengi...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Giuseppe Pipitone [verfasserIn] Stefano Di Bella [verfasserIn] Alberto Enrico Maraolo [verfasserIn] Guido Granata [verfasserIn] Milo Gatti [verfasserIn] Luigi Principe [verfasserIn] Alessandro Russo [verfasserIn] Andrea Gizzi [verfasserIn] Rita Pallone [verfasserIn] Antonio Cascio [verfasserIn] Chiara Iaria [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2023

Schlagwörter:	fosfomycin multidrug resistance difficult-to-treat

Übergeordnetes Werk:	In: Antibiotics - MDPI AG, 2013, 12(2023), 12, p 1653
Übergeordnetes Werk:	volume:12 ; year:2023 ; number:12, p 1653

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.3390/antibiotics12121653

Katalog-ID:	DOAJ098922181

Internformat


LEADER	01000naa a22002652 4500
001	DOAJ098922181
003	DE-627
005	20240414004808.0
007	cr uuu---uuuuu
008	240414s2023 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.3390/antibiotics12121653 \|2 doi
035			\|a (DE-627)DOAJ098922181
035			\|a (DE-599)DOAJ5fab61fdcab54785a2464f804d11d18b
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RM1-950
100	0		\|a Giuseppe Pipitone \|e verfasserin \|4 aut
245	1	0	\|a Intravenous Fosfomycin for Systemic Multidrug-Resistant <i<Pseudomonas aeruginosa</i< Infections
264		1	\|c 2023
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Human <i<Pseudomonas</i< infections have high morbidity and mortality rates. <i<Pseudomonas</i< bacteria can cause sepsis or septic shock; they produce biofilm and commonly exhibit a multidrug-resistant phenotype. The choice of antimicrobial therapy in many cases is challenging, and deep knowledge of clinical, microbiological, and pharmacological issues is required. Intravenous fosfomycin is being repurposed in a combination given its favorable pharmacokinetic/pharmacodynamic properties (a small molecule with favorable kinetic both in bloodstream infection and in deep-seated infections), antibiofilm activity, and its interesting synergistic effects with other antimicrobials. Recent literature on epidemiological, microbiological, pharmacological, and clinical data on intravenous fosfomycin therapy against <i<Pseudomonas</i< is herein reviewed and discussed.
650		4	\|a fosfomycin
650		4	\|a <i<Pseudomonas aeruginosa</i<
650		4	\|a multidrug resistance
650		4	\|a difficult-to-treat <i<P. aeruginosa</i<
653		0	\|a Therapeutics. Pharmacology
700	0		\|a Stefano Di Bella \|e verfasserin \|4 aut
700	0		\|a Alberto Enrico Maraolo \|e verfasserin \|4 aut
700	0		\|a Guido Granata \|e verfasserin \|4 aut
700	0		\|a Milo Gatti \|e verfasserin \|4 aut
700	0		\|a Luigi Principe \|e verfasserin \|4 aut
700	0		\|a Alessandro Russo \|e verfasserin \|4 aut
700	0		\|a Andrea Gizzi \|e verfasserin \|4 aut
700	0		\|a Rita Pallone \|e verfasserin \|4 aut
700	0		\|a Antonio Cascio \|e verfasserin \|4 aut
700	0		\|a Chiara Iaria \|e verfasserin \|4 aut
773	0	8	\|i In \|t Antibiotics \|d MDPI AG, 2013 \|g 12(2023), 12, p 1653 \|w (DE-627)726120596 \|w (DE-600)2681345-2 \|x 20796382 \|7 nnns
773	1	8	\|g volume:12 \|g year:2023 \|g number:12, p 1653
856	4	0	\|u https://doi.org/10.3390/antibiotics12121653 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/5fab61fdcab54785a2464f804d11d18b \|z kostenfrei
856	4	0	\|u https://www.mdpi.com/2079-6382/12/12/1653 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2079-6382 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 12 \|j 2023 \|e 12, p 1653

Indexfelder

author_variant	g p gp s d b sdb a e m aem g g gg m g mg l p lp a r ar a g ag r p rp a c ac c i ci
matchkey_str	article:20796382:2023----::nrvnufsoyifrytmcutdurssatpedmn
hierarchy_sort_str	2023
callnumber-subject-code	RM
publishDate	2023
allfields	10.3390/antibiotics12121653 doi (DE-627)DOAJ098922181 (DE-599)DOAJ5fab61fdcab54785a2464f804d11d18b DE-627 ger DE-627 rakwb eng RM1-950 Giuseppe Pipitone verfasserin aut Intravenous Fosfomycin for Systemic Multidrug-Resistant <i<Pseudomonas aeruginosa</i< Infections 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Human <i<Pseudomonas</i< infections have high morbidity and mortality rates. <i<Pseudomonas</i< bacteria can cause sepsis or septic shock; they produce biofilm and commonly exhibit a multidrug-resistant phenotype. The choice of antimicrobial therapy in many cases is challenging, and deep knowledge of clinical, microbiological, and pharmacological issues is required. Intravenous fosfomycin is being repurposed in a combination given its favorable pharmacokinetic/pharmacodynamic properties (a small molecule with favorable kinetic both in bloodstream infection and in deep-seated infections), antibiofilm activity, and its interesting synergistic effects with other antimicrobials. Recent literature on epidemiological, microbiological, pharmacological, and clinical data on intravenous fosfomycin therapy against <i<Pseudomonas</i< is herein reviewed and discussed. fosfomycin <i<Pseudomonas aeruginosa</i< multidrug resistance difficult-to-treat <i<P. aeruginosa</i< Therapeutics. Pharmacology Stefano Di Bella verfasserin aut Alberto Enrico Maraolo verfasserin aut Guido Granata verfasserin aut Milo Gatti verfasserin aut Luigi Principe verfasserin aut Alessandro Russo verfasserin aut Andrea Gizzi verfasserin aut Rita Pallone verfasserin aut Antonio Cascio verfasserin aut Chiara Iaria verfasserin aut In Antibiotics MDPI AG, 2013 12(2023), 12, p 1653 (DE-627)726120596 (DE-600)2681345-2 20796382 nnns volume:12 year:2023 number:12, p 1653 https://doi.org/10.3390/antibiotics12121653 kostenfrei https://doaj.org/article/5fab61fdcab54785a2464f804d11d18b kostenfrei https://www.mdpi.com/2079-6382/12/12/1653 kostenfrei https://doaj.org/toc/2079-6382 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2023 12, p 1653
spelling	10.3390/antibiotics12121653 doi (DE-627)DOAJ098922181 (DE-599)DOAJ5fab61fdcab54785a2464f804d11d18b DE-627 ger DE-627 rakwb eng RM1-950 Giuseppe Pipitone verfasserin aut Intravenous Fosfomycin for Systemic Multidrug-Resistant <i<Pseudomonas aeruginosa</i< Infections 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Human <i<Pseudomonas</i< infections have high morbidity and mortality rates. <i<Pseudomonas</i< bacteria can cause sepsis or septic shock; they produce biofilm and commonly exhibit a multidrug-resistant phenotype. The choice of antimicrobial therapy in many cases is challenging, and deep knowledge of clinical, microbiological, and pharmacological issues is required. Intravenous fosfomycin is being repurposed in a combination given its favorable pharmacokinetic/pharmacodynamic properties (a small molecule with favorable kinetic both in bloodstream infection and in deep-seated infections), antibiofilm activity, and its interesting synergistic effects with other antimicrobials. Recent literature on epidemiological, microbiological, pharmacological, and clinical data on intravenous fosfomycin therapy against <i<Pseudomonas</i< is herein reviewed and discussed. fosfomycin <i<Pseudomonas aeruginosa</i< multidrug resistance difficult-to-treat <i<P. aeruginosa</i< Therapeutics. Pharmacology Stefano Di Bella verfasserin aut Alberto Enrico Maraolo verfasserin aut Guido Granata verfasserin aut Milo Gatti verfasserin aut Luigi Principe verfasserin aut Alessandro Russo verfasserin aut Andrea Gizzi verfasserin aut Rita Pallone verfasserin aut Antonio Cascio verfasserin aut Chiara Iaria verfasserin aut In Antibiotics MDPI AG, 2013 12(2023), 12, p 1653 (DE-627)726120596 (DE-600)2681345-2 20796382 nnns volume:12 year:2023 number:12, p 1653 https://doi.org/10.3390/antibiotics12121653 kostenfrei https://doaj.org/article/5fab61fdcab54785a2464f804d11d18b kostenfrei https://www.mdpi.com/2079-6382/12/12/1653 kostenfrei https://doaj.org/toc/2079-6382 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2023 12, p 1653
allfields_unstemmed	10.3390/antibiotics12121653 doi (DE-627)DOAJ098922181 (DE-599)DOAJ5fab61fdcab54785a2464f804d11d18b DE-627 ger DE-627 rakwb eng RM1-950 Giuseppe Pipitone verfasserin aut Intravenous Fosfomycin for Systemic Multidrug-Resistant <i<Pseudomonas aeruginosa</i< Infections 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Human <i<Pseudomonas</i< infections have high morbidity and mortality rates. <i<Pseudomonas</i< bacteria can cause sepsis or septic shock; they produce biofilm and commonly exhibit a multidrug-resistant phenotype. The choice of antimicrobial therapy in many cases is challenging, and deep knowledge of clinical, microbiological, and pharmacological issues is required. Intravenous fosfomycin is being repurposed in a combination given its favorable pharmacokinetic/pharmacodynamic properties (a small molecule with favorable kinetic both in bloodstream infection and in deep-seated infections), antibiofilm activity, and its interesting synergistic effects with other antimicrobials. Recent literature on epidemiological, microbiological, pharmacological, and clinical data on intravenous fosfomycin therapy against <i<Pseudomonas</i< is herein reviewed and discussed. fosfomycin <i<Pseudomonas aeruginosa</i< multidrug resistance difficult-to-treat <i<P. aeruginosa</i< Therapeutics. Pharmacology Stefano Di Bella verfasserin aut Alberto Enrico Maraolo verfasserin aut Guido Granata verfasserin aut Milo Gatti verfasserin aut Luigi Principe verfasserin aut Alessandro Russo verfasserin aut Andrea Gizzi verfasserin aut Rita Pallone verfasserin aut Antonio Cascio verfasserin aut Chiara Iaria verfasserin aut In Antibiotics MDPI AG, 2013 12(2023), 12, p 1653 (DE-627)726120596 (DE-600)2681345-2 20796382 nnns volume:12 year:2023 number:12, p 1653 https://doi.org/10.3390/antibiotics12121653 kostenfrei https://doaj.org/article/5fab61fdcab54785a2464f804d11d18b kostenfrei https://www.mdpi.com/2079-6382/12/12/1653 kostenfrei https://doaj.org/toc/2079-6382 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2023 12, p 1653
allfieldsGer	10.3390/antibiotics12121653 doi (DE-627)DOAJ098922181 (DE-599)DOAJ5fab61fdcab54785a2464f804d11d18b DE-627 ger DE-627 rakwb eng RM1-950 Giuseppe Pipitone verfasserin aut Intravenous Fosfomycin for Systemic Multidrug-Resistant <i<Pseudomonas aeruginosa</i< Infections 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Human <i<Pseudomonas</i< infections have high morbidity and mortality rates. <i<Pseudomonas</i< bacteria can cause sepsis or septic shock; they produce biofilm and commonly exhibit a multidrug-resistant phenotype. The choice of antimicrobial therapy in many cases is challenging, and deep knowledge of clinical, microbiological, and pharmacological issues is required. Intravenous fosfomycin is being repurposed in a combination given its favorable pharmacokinetic/pharmacodynamic properties (a small molecule with favorable kinetic both in bloodstream infection and in deep-seated infections), antibiofilm activity, and its interesting synergistic effects with other antimicrobials. Recent literature on epidemiological, microbiological, pharmacological, and clinical data on intravenous fosfomycin therapy against <i<Pseudomonas</i< is herein reviewed and discussed. fosfomycin <i<Pseudomonas aeruginosa</i< multidrug resistance difficult-to-treat <i<P. aeruginosa</i< Therapeutics. Pharmacology Stefano Di Bella verfasserin aut Alberto Enrico Maraolo verfasserin aut Guido Granata verfasserin aut Milo Gatti verfasserin aut Luigi Principe verfasserin aut Alessandro Russo verfasserin aut Andrea Gizzi verfasserin aut Rita Pallone verfasserin aut Antonio Cascio verfasserin aut Chiara Iaria verfasserin aut In Antibiotics MDPI AG, 2013 12(2023), 12, p 1653 (DE-627)726120596 (DE-600)2681345-2 20796382 nnns volume:12 year:2023 number:12, p 1653 https://doi.org/10.3390/antibiotics12121653 kostenfrei https://doaj.org/article/5fab61fdcab54785a2464f804d11d18b kostenfrei https://www.mdpi.com/2079-6382/12/12/1653 kostenfrei https://doaj.org/toc/2079-6382 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2023 12, p 1653
allfieldsSound	10.3390/antibiotics12121653 doi (DE-627)DOAJ098922181 (DE-599)DOAJ5fab61fdcab54785a2464f804d11d18b DE-627 ger DE-627 rakwb eng RM1-950 Giuseppe Pipitone verfasserin aut Intravenous Fosfomycin for Systemic Multidrug-Resistant <i<Pseudomonas aeruginosa</i< Infections 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Human <i<Pseudomonas</i< infections have high morbidity and mortality rates. <i<Pseudomonas</i< bacteria can cause sepsis or septic shock; they produce biofilm and commonly exhibit a multidrug-resistant phenotype. The choice of antimicrobial therapy in many cases is challenging, and deep knowledge of clinical, microbiological, and pharmacological issues is required. Intravenous fosfomycin is being repurposed in a combination given its favorable pharmacokinetic/pharmacodynamic properties (a small molecule with favorable kinetic both in bloodstream infection and in deep-seated infections), antibiofilm activity, and its interesting synergistic effects with other antimicrobials. Recent literature on epidemiological, microbiological, pharmacological, and clinical data on intravenous fosfomycin therapy against <i<Pseudomonas</i< is herein reviewed and discussed. fosfomycin <i<Pseudomonas aeruginosa</i< multidrug resistance difficult-to-treat <i<P. aeruginosa</i< Therapeutics. Pharmacology Stefano Di Bella verfasserin aut Alberto Enrico Maraolo verfasserin aut Guido Granata verfasserin aut Milo Gatti verfasserin aut Luigi Principe verfasserin aut Alessandro Russo verfasserin aut Andrea Gizzi verfasserin aut Rita Pallone verfasserin aut Antonio Cascio verfasserin aut Chiara Iaria verfasserin aut In Antibiotics MDPI AG, 2013 12(2023), 12, p 1653 (DE-627)726120596 (DE-600)2681345-2 20796382 nnns volume:12 year:2023 number:12, p 1653 https://doi.org/10.3390/antibiotics12121653 kostenfrei https://doaj.org/article/5fab61fdcab54785a2464f804d11d18b kostenfrei https://www.mdpi.com/2079-6382/12/12/1653 kostenfrei https://doaj.org/toc/2079-6382 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2023 12, p 1653
language	English
source	In Antibiotics 12(2023), 12, p 1653 volume:12 year:2023 number:12, p 1653
sourceStr	In Antibiotics 12(2023), 12, p 1653 volume:12 year:2023 number:12, p 1653
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	fosfomycin <i<Pseudomonas aeruginosa</i< multidrug resistance difficult-to-treat <i<P. aeruginosa</i< Therapeutics. Pharmacology
isfreeaccess_bool	true
container_title	Antibiotics
authorswithroles_txt_mv	Giuseppe Pipitone @@aut@@ Stefano Di Bella @@aut@@ Alberto Enrico Maraolo @@aut@@ Guido Granata @@aut@@ Milo Gatti @@aut@@ Luigi Principe @@aut@@ Alessandro Russo @@aut@@ Andrea Gizzi @@aut@@ Rita Pallone @@aut@@ Antonio Cascio @@aut@@ Chiara Iaria @@aut@@
publishDateDaySort_date	2023-01-01T00:00:00Z
hierarchy_top_id	726120596
id	DOAJ098922181
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ098922181</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414004808.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240414s2023 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/antibiotics12121653</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ098922181</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ5fab61fdcab54785a2464f804d11d18b</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Giuseppe Pipitone</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Intravenous Fosfomycin for Systemic Multidrug-Resistant <i<Pseudomonas aeruginosa</i< Infections</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Human <i<Pseudomonas</i< infections have high morbidity and mortality rates. <i<Pseudomonas</i< bacteria can cause sepsis or septic shock; they produce biofilm and commonly exhibit a multidrug-resistant phenotype. The choice of antimicrobial therapy in many cases is challenging, and deep knowledge of clinical, microbiological, and pharmacological issues is required. Intravenous fosfomycin is being repurposed in a combination given its favorable pharmacokinetic/pharmacodynamic properties (a small molecule with favorable kinetic both in bloodstream infection and in deep-seated infections), antibiofilm activity, and its interesting synergistic effects with other antimicrobials. Recent literature on epidemiological, microbiological, pharmacological, and clinical data on intravenous fosfomycin therapy against <i<Pseudomonas</i< is herein reviewed and discussed.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">fosfomycin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a"><i<Pseudomonas aeruginosa</i<</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">multidrug resistance</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">difficult-to-treat <i<P. aeruginosa</i<</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stefano Di Bella</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alberto Enrico Maraolo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Guido Granata</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Milo Gatti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Luigi Principe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alessandro Russo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Andrea Gizzi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rita Pallone</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Antonio Cascio</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Chiara Iaria</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Antibiotics</subfield><subfield code="d">MDPI AG, 2013</subfield><subfield code="g">12(2023), 12, p 1653</subfield><subfield code="w">(DE-627)726120596</subfield><subfield code="w">(DE-600)2681345-2</subfield><subfield code="x">20796382</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:12</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:12, p 1653</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/antibiotics12121653</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/5fab61fdcab54785a2464f804d11d18b</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2079-6382/12/12/1653</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2079-6382</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">12</subfield><subfield code="j">2023</subfield><subfield code="e">12, p 1653</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Giuseppe Pipitone
spellingShingle	Giuseppe Pipitone misc RM1-950 misc fosfomycin misc <i<Pseudomonas aeruginosa</i< misc multidrug resistance misc difficult-to-treat <i<P. aeruginosa</i< misc Therapeutics. Pharmacology Intravenous Fosfomycin for Systemic Multidrug-Resistant <i<Pseudomonas aeruginosa</i< Infections
authorStr	Giuseppe Pipitone
ppnlink_with_tag_str_mv	@@773@@(DE-627)726120596
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RM1-950
illustrated	Not Illustrated
issn	20796382
topic_title	RM1-950 Intravenous Fosfomycin for Systemic Multidrug-Resistant <i<Pseudomonas aeruginosa</i< Infections fosfomycin <i<Pseudomonas aeruginosa</i< multidrug resistance difficult-to-treat <i<P. aeruginosa</i<
topic	misc RM1-950 misc fosfomycin misc <i<Pseudomonas aeruginosa</i< misc multidrug resistance misc difficult-to-treat <i<P. aeruginosa</i< misc Therapeutics. Pharmacology
topic_unstemmed	misc RM1-950 misc fosfomycin misc <i<Pseudomonas aeruginosa</i< misc multidrug resistance misc difficult-to-treat <i<P. aeruginosa</i< misc Therapeutics. Pharmacology
topic_browse	misc RM1-950 misc fosfomycin misc <i<Pseudomonas aeruginosa</i< misc multidrug resistance misc difficult-to-treat <i<P. aeruginosa</i< misc Therapeutics. Pharmacology
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Antibiotics
hierarchy_parent_id	726120596
hierarchy_top_title	Antibiotics
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)726120596 (DE-600)2681345-2
title	Intravenous Fosfomycin for Systemic Multidrug-Resistant <i<Pseudomonas aeruginosa</i< Infections
ctrlnum	(DE-627)DOAJ098922181 (DE-599)DOAJ5fab61fdcab54785a2464f804d11d18b
title_full	Intravenous Fosfomycin for Systemic Multidrug-Resistant <i<Pseudomonas aeruginosa</i< Infections
author_sort	Giuseppe Pipitone
journal	Antibiotics
journalStr	Antibiotics
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2023
contenttype_str_mv	txt
author_browse	Giuseppe Pipitone Stefano Di Bella Alberto Enrico Maraolo Guido Granata Milo Gatti Luigi Principe Alessandro Russo Andrea Gizzi Rita Pallone Antonio Cascio Chiara Iaria
container_volume	12
class	RM1-950
format_se	Elektronische Aufsätze
author-letter	Giuseppe Pipitone
doi_str_mv	10.3390/antibiotics12121653
author2-role	verfasserin
title_sort	intravenous fosfomycin for systemic multidrug-resistant <i<pseudomonas aeruginosa</i< infections
callnumber	RM1-950
title_auth	Intravenous Fosfomycin for Systemic Multidrug-Resistant <i<Pseudomonas aeruginosa</i< Infections
abstract	Human <i<Pseudomonas</i< infections have high morbidity and mortality rates. <i<Pseudomonas</i< bacteria can cause sepsis or septic shock; they produce biofilm and commonly exhibit a multidrug-resistant phenotype. The choice of antimicrobial therapy in many cases is challenging, and deep knowledge of clinical, microbiological, and pharmacological issues is required. Intravenous fosfomycin is being repurposed in a combination given its favorable pharmacokinetic/pharmacodynamic properties (a small molecule with favorable kinetic both in bloodstream infection and in deep-seated infections), antibiofilm activity, and its interesting synergistic effects with other antimicrobials. Recent literature on epidemiological, microbiological, pharmacological, and clinical data on intravenous fosfomycin therapy against <i<Pseudomonas</i< is herein reviewed and discussed.
abstractGer	Human <i<Pseudomonas</i< infections have high morbidity and mortality rates. <i<Pseudomonas</i< bacteria can cause sepsis or septic shock; they produce biofilm and commonly exhibit a multidrug-resistant phenotype. The choice of antimicrobial therapy in many cases is challenging, and deep knowledge of clinical, microbiological, and pharmacological issues is required. Intravenous fosfomycin is being repurposed in a combination given its favorable pharmacokinetic/pharmacodynamic properties (a small molecule with favorable kinetic both in bloodstream infection and in deep-seated infections), antibiofilm activity, and its interesting synergistic effects with other antimicrobials. Recent literature on epidemiological, microbiological, pharmacological, and clinical data on intravenous fosfomycin therapy against <i<Pseudomonas</i< is herein reviewed and discussed.
abstract_unstemmed	Human <i<Pseudomonas</i< infections have high morbidity and mortality rates. <i<Pseudomonas</i< bacteria can cause sepsis or septic shock; they produce biofilm and commonly exhibit a multidrug-resistant phenotype. The choice of antimicrobial therapy in many cases is challenging, and deep knowledge of clinical, microbiological, and pharmacological issues is required. Intravenous fosfomycin is being repurposed in a combination given its favorable pharmacokinetic/pharmacodynamic properties (a small molecule with favorable kinetic both in bloodstream infection and in deep-seated infections), antibiofilm activity, and its interesting synergistic effects with other antimicrobials. Recent literature on epidemiological, microbiological, pharmacological, and clinical data on intravenous fosfomycin therapy against <i<Pseudomonas</i< is herein reviewed and discussed.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	12, p 1653
title_short	Intravenous Fosfomycin for Systemic Multidrug-Resistant <i<Pseudomonas aeruginosa</i< Infections
url	https://doi.org/10.3390/antibiotics12121653 https://doaj.org/article/5fab61fdcab54785a2464f804d11d18b https://www.mdpi.com/2079-6382/12/12/1653 https://doaj.org/toc/2079-6382
remote_bool	true
author2	Stefano Di Bella Alberto Enrico Maraolo Guido Granata Milo Gatti Luigi Principe Alessandro Russo Andrea Gizzi Rita Pallone Antonio Cascio Chiara Iaria
author2Str	Stefano Di Bella Alberto Enrico Maraolo Guido Granata Milo Gatti Luigi Principe Alessandro Russo Andrea Gizzi Rita Pallone Antonio Cascio Chiara Iaria
ppnlink	726120596
callnumber-subject	RM - Therapeutics and Pharmacology
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.3390/antibiotics12121653
callnumber-a	RM1-950
up_date	2024-07-03T20:00:31.217Z
_version_	1803589340334391297
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ098922181</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414004808.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240414s2023 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/antibiotics12121653</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ098922181</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ5fab61fdcab54785a2464f804d11d18b</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Giuseppe Pipitone</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Intravenous Fosfomycin for Systemic Multidrug-Resistant <i<Pseudomonas aeruginosa</i< Infections</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Human <i<Pseudomonas</i< infections have high morbidity and mortality rates. <i<Pseudomonas</i< bacteria can cause sepsis or septic shock; they produce biofilm and commonly exhibit a multidrug-resistant phenotype. The choice of antimicrobial therapy in many cases is challenging, and deep knowledge of clinical, microbiological, and pharmacological issues is required. Intravenous fosfomycin is being repurposed in a combination given its favorable pharmacokinetic/pharmacodynamic properties (a small molecule with favorable kinetic both in bloodstream infection and in deep-seated infections), antibiofilm activity, and its interesting synergistic effects with other antimicrobials. Recent literature on epidemiological, microbiological, pharmacological, and clinical data on intravenous fosfomycin therapy against <i<Pseudomonas</i< is herein reviewed and discussed.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">fosfomycin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a"><i<Pseudomonas aeruginosa</i<</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">multidrug resistance</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">difficult-to-treat <i<P. aeruginosa</i<</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stefano Di Bella</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alberto Enrico Maraolo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Guido Granata</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Milo Gatti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Luigi Principe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alessandro Russo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Andrea Gizzi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rita Pallone</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Antonio Cascio</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Chiara Iaria</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Antibiotics</subfield><subfield code="d">MDPI AG, 2013</subfield><subfield code="g">12(2023), 12, p 1653</subfield><subfield code="w">(DE-627)726120596</subfield><subfield code="w">(DE-600)2681345-2</subfield><subfield code="x">20796382</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:12</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:12, p 1653</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/antibiotics12121653</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/5fab61fdcab54785a2464f804d11d18b</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2079-6382/12/12/1653</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2079-6382</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">12</subfield><subfield code="j">2023</subfield><subfield code="e">12, p 1653</subfield></datafield></record></collection>
score	7.4002275

Nicht das Richtige dabei?

Schreiben Sie uns!

Intravenous Fosfomycin for Systemic Multidrug-Resistant <i<Pseudomonas aeruginosa</i< Infections

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?